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Abstract
Background: The soluble forms of vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1
(sICAM-1) have been found to be increased in the blood of patients with Graves’ disease. The aim of this study is evaluation
of the serum concentrations of soluble forms of adhesion molecules ICAM-1 and VCAM-1 in patients with thyroid-associa-
ted orbitopathy (TAO) before and after methylprednisolone treatment.
Material and methods: The study was performed in 40 Graves’disease, hyperthyroid and euthyroid patients with a clini-
cally active form of TAO. Serum concentrations of sVCAM-1 and sICAM-1 in TAO patients were determined by enzyme-
linked immunoabsorbent assay (ELISA) before and after intensive pulse methylprednisolone treatment.
Results: We did not find any significant changes in the studied parameters between TAO patients with hyperthyroidism
and those with euthyroidism. The serum concentrations of sICAM-1 and sVCAM-1 were significantly increased in patients
with TAO before methylprednisolone therapy when compared with the control group. After treatment serum concentra-
tions of sICAM-1 and sVCAM-1 decreased significantly but were still significantly higher than for the control group.
Conclusion: From the results obtained we can conclude that Graves’ orbitopathy itself but not thyroid function is probably
responsible for the elevated level of the adhesion molecules studied.
(Pol J Endocrinol 2007; 58 (6): 487–491)
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Streszczenie
Wstęp: Stężenie rozpuszczalnych form cząstek adhezyjnych między innymi międzykomórkowej cząstki adhezyjnej-1
(sICAM-1) oraz naczyniowej cząstki adhezyjnej-1 wzrasta w surowicy krwi chorych na chorobę Gravesa. Celem pracy była
ocena stężenia sICAM-1oraz sVCAM-1 u chorych na chorobę Gravesa powikłaną aktywną formą orbitopatii tarczycowej
przed oraz po leczeniu immunosupresyjnym.
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sICAM-1 and sVCAM-1 in active thyroid orbitopathy
Materiał i metody: Badania przeprowadzono w grupie 40 chorych na chorobę Gravesa (w stanie hyper- oraz eutyreozy)
powikłaną wystąpieniem aktywnej formy orbiopatii tarczycowej. Stężenie sICAM-1oraz sVCAM-1 w surowicy krwi ozna-
czano metodą immunoenzymatyczną (ELISA) przed oraz po leczeniu pulsami dożylnymi metylprednisolonu.
Wyniki: Nie wykazano istotnej statystycznie różnicy w stężeniu badanych cząstek adhezyjnych między chorymi na cho-
robę Gravesa w stanie nadczynności tarczycy oraz w eutyreozie powikłaną aktywną orbitopatią tarczycową. Stężenie sI-
CAM-1oraz sVCAM-1 było znamiennie statystycznie podwyższone u chorych przed leczeniem pulsami metylprednisolo-
nu w porównaniu z grupą kontrolną. Po leczeniu stężenie cząstek adhezyjnych uległo znamiennemu statystycznie obni-
żeniu.
Wnioski: Na podstawie uzyskanych wyników można wnioskować, że prawdopodobnie orbitopatia tarczycowa, a nie stan
metaboliczny tarczycy, odpowiedzialny jest za wzrost stężenia badanych cząstek adhezyjnych.
(Endokrynol Pol 2007; 58 (6): 487–491)
Słowa kluczowe: cząstki adhezyjne, choroba Gravesa, orbitopatia tarczycowa
Introduction
Thyroid-associated orbitopathy (TAO) is an autoimmu-
ne condition characterised by mononuclear cell infil-
tration of the extraocular muscles (EOM) and/or the
orbital fat/connective tissue and proliferation and dif-
ferentiation of fibroblasts to fibroadipocytes and adipo-
cytes with associated deposition of glycosaminoglycans
in the interstitial spaces [1].
Adhesion molecules play an important role in the
initiation and maintenance of the inflammatory immune
process. Cellular activation and local expression of adhe-
sion molecules lead to leukocyte recruitment, migration
to inflammatory sites and targeting in the extravascular
space [2]. Cell adhesion molecules mediate rolling and tran-
sendothelial migration of circulating leucocytes and may
thus direct inflammatory cells into the intima [3]. Soluble
forms of the adhesion molecules are detectable in the pla-
sma. The physiological functions of these soluble forms
are unclear but their concentration may reflect the expres-
sion on the leucocytes and endothelial cells. Soluble forms
of various cell adhesion molecules, such as intercellular
adhesion molecule-1 (ICAM-1), vascular adhesion mole-
cule-1 (VCAM-1), endothelial leukocyte adhesion mole-
cule-1 (ELAM-1) and E-selectin, may be related to the ef-
fects of various diseases [4–6] although the results are in-
consistent and often ambiguous.
The aim of this study is to evaluate serum concen-
trations of soluble forms of adhesion molecules ICAM-
1 and VCAM-1 and the possible role of these adhesion
molecules as laboratory markers in the assessment of
TAO activity.
Material and methods
The study was performed on a group of 40 patients with
a first episode of a clinically active form of TAO (clinical
activity score > 4 points) and a severity of orbitopathy
classified as stages 3c to 5a in the NO SPECS system
(0, no signs or symptoms; 1, only signs, no symptoms;
2, soft tissue involvement; 3, proptosis; 4, extraocular mu-
scle involvement; 5, corneal involvement; 6, sight loss due
to optic nerve involvement). Of these patients
20 were in hyperthyreosis (group 1) and 20 in euthyreosis
(group 2) and all were on thiamazole therapy. The control
group consisted of 30 healthy age-matched subjects. In
the numerical system given each class of eye change rece-
ived a score on a scale from 0 to 3 according to the degree
of involvement; after the scores were totalled, a Total Eye
Score was derived, ranging from 0 to 15 points.
The basal characteristics of the patients with TAO
are presented in Table 1. The inclusion criteria for the
study were as follows:
— diagnosis of Graves’ disease based on clinical and
laboratory findings: fT4, fT3, TSH, TSH-receptor
antibodies (TRAB), anti-thyroid peroxidase antibo-
dies (TPO-Ab) and thyroid USG scans;
— an ophthalmological examination confirming an
active stage of TAO: clinical activity score (CAS)
> 4 points [7] and magnetic resonance (MR) scans
of the orbit.
Exclusion criteria were any other autoimmune or
active infectious diseases. Serum concentrations of
sVCAM-1 and sICAM-1 were determined by enzyme-
linked immunoabsorbent assay (ELISA, Quantikine,
R&D Systems, USA) before and after intensive pulse
methylprednisolone treatment (1.0 g per day every
other day to the cumulative dose of 9.0 to 12.0 grams
during 3–4 week). Intra-assay precision for VCAM-1 was
3.4% and for ICAM-1 4.5%. The differences in distribu-
tion of the studied parameters between the TAO pa-
tients and the control group were evaluated by the
c² test. The statistical analysis was carried out using the
“Statistica 5.0 Pl” programme. Data were analysed by
the non-parametric Mann-Whitney U-test, assuming
the levels p < 0.05 as statistically significant.
All the subjects gave their formal consent before
participating in the study, and the research followed
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Basal clinical characteristics of the patients and serum concentrations of the soluble intercellular adhesion molecule-1 (sICAM-1)
and vascular adhesion molecule-1 (sVCAM-1) in hyperthyroid and euthyroid  patients with active thyroid-associated
orbitopathy (TAO)
Tabela I
Wyjściowa charakterystyka i stężenia rozpuszczalnej międzykomórkowej cząstki adhezyjnej-1 (sICAM-1) i naczyniowej cząstki
adhezyjnej-1 (sVCAM-1) w surowicy krwi u osób z aktywną formą orbitopatii tarczycowej (TAO) w stanie hyper- oraz eutyreozy
Group 1 hyperthyroid Group 2 euthyroid p
TAO patients (n=20) TAO patients  (n=20) Mann-Whitney U-test
Age (years) 45.11±9.07 53.08±8.82 NS  p=0.057
Thyrotropin (TSH)  [µIU/ml] 0.2±0.5 3.38±1.8 p<0.05
free T4 [ng/dl] 3.42±2.91 1.26±0.4 p<0.05
CAS (clinical activity score) (points) 5.10±1.85 5.16±0.83 NS p=0.911
Total Eye Score (points) 9.15±2.1 8.34±1.5 NS p=0.24
TRAB [IU/l] 21.7±4.55 18.9 ±2.38 NS p= 0.062
TPO-Ab [IU/l] 257.50±401.91 216.65±288.49 NS  p=0.798
sICAM-1 before methylprednisolone therapy [ng/ml] 148.55±7.69 151.65±10.35 NS p=0.441
sICAM-1 after methylprednisolone therapy [ng/ml] 134.69±6.77 136.95±7.00 NS p=0.451
sVCAM-1 before methylprednisolone therapy [ng/ml] 1119.82±112.82 1180.68±142.63 NS  p=0.287
sVCAM-1after methylprednisolone therapy [ng/ml] 1020.57±73.92 1076.67±130.11 NS  p=0.241
values are means ± standard deviation, TAO - thyroid-associated orbitopathy, TRAB — TSH-receptor antibodies, TPO-Ab — anti-thyroid peroxidase
antibodies,  sICAM-1 — soluble intercellular adhesion molecule-1, sVCAM-1 — soluble vascular adhesion molecule-1, CAS — Clinical Activity Score of
TAO,  NS — not significant
the tenets of the Declaration of Helsinki. The project was
carried out with the permission of The Bioethical Board
of the Medical University of Silesia NN 013–275/01/02.
Results
The results of the study are presented in Tables 1 and 2.
We did not find any significant changes in sVCAM-1
and sICAM-1 blood concentration  between the TAO
hyperthyroid patients (group 1) and the TAO euthyro-
id patients (group 2). See Table 1.
As there was no statistical difference in the studied
parameters between patients from group 1 and those
from 2, all the patients were considered as a new study
group (group 3: patients with active TAO, n = 40) in
the further statistical analysis.
Serum concentrations of sVCAM-1 were significan-
tly increased in patients from group 3 (with TAO) befo-
re methylprednisolone therapy when compared with
the control group (1153.01 ± 130.67 ng/ml vs. 910.69 ±
37.26 ng/ml p < 0.0005). After treatment serum concen-
trations of sVCAM-1 decreased (1051.17 ± 109.67 ng/ml)
but were still significantly higher than for the control
group (p < 0.0005) (Table 2). Serum concentrations of
sICAM-1 were also significantly increased in patients
with TAO before methylprednisolone therapy when
compared with the control group (150.245 ± 9.16 ng/ml
vs. 128.79 ± 6.68 ng/ml, p < 0.0005) and also significantly
decreased after methylprednisolone therapy (135.92 ±
± 6.83 ng/ml) (Table 2). Serum concentrations of
sVCAM-1 and sICAM-1 in patients with active thyroid-
associated ophthalmopathy decreased significantly after
methylprednisolone treatment in comparison with con-
centrations before treatment (Table 2).
Discussion
Proinflammatory cytokines induce the expression of
endothelial cell adhesion molecules on the lumenal sur-
face of the vascular endothelium, subsequently incre-
asing leukocyte adhesion, which is the principal me-
chanism of inflammation [8].
Interactions between activated T lymphocytes and
orbital endothelial cells are mediated by integrin-depen-
dent ICAM-1/LFA-1 and VCAM-1/VLA-4 pathways [2].
Positive staining for ICAM-1, lymphocyte function-asso-
ciated antigen-1 (LFA-1) and very late antigen-4 (VLA-4)
were found on infiltrating mononuclear cells. Postca-
pillary vascular endothelial cells expressed increased
ELAM-1, but not VCAM-1. These results suggest that
the LFA-1/ICAM-1 and ELAM-1 pathways may be re-
sponsible for the migration of mononuclear cells into
the thyroid glands of patients with Graves’ disease and
that the VLA-4/VCAM-1 pathway plays a critical role in
the cellular interactions that lead to the formation of
B-memory cells and the excess production of antibo-
490













sICAM-1 and sVCAM-1 in active thyroid orbitopathy
Table II
Serum concentration of soluble intercellular adhesion molecule-1(sICAM-1) and vascular adhesion molecule-1 (sVCAM-1)
in control group and in patients with active thyroid-associated orbitopathy (TAO) before and after methylprednisolone  therapy
Tabela II
Stężenia rozpuszczalnej międzykomórkowej cząstki adhezyjnej-1 (sICAM-1) i naczyniowej cząstki adhezyjnej-1 (sVCAM-1)
w surowicy krwi u osób z grupy kontrolnej i u chorych z aktywną formą orbitopatii tarczycowej (TAO) przed i po leczeniu
metylprednizolonem
sICAM-1 sVCAM-1
Control (n=30) [ng/ml] 128.79±6.68 910.69±37.26
Group 3 TAO before methylprednisolone treatment (n=40) [ng/ml] 150.245±9.16 1153.01±130.67
p<0.0005* p<0.0005*
Group 3 TAO after methylprednisolone treatment (n=40) [ng/ml] 135.92±6.83 1051.17±109.67
p<0.05** p<0.0005**
p<0.0005*** p<0.0005***
TAO — thyroid-associated orbitopathy, *control vs. patients with TAO before methylprednisolone therapy, **control vs. patients with TAO after
methylprednisolone therapy, ***patients with TAO before methylprednisolone therapy vs. patients with TAO after methylprednisolone  therapy
dies [9]. Higher soluble ICAM-1 concentrations in pa-
tients with Graves’ disease with TAO than those with
Graves’ disease without orbitopathy can reflect the de-
gree of inflammatory activity. Increased soluble ELAM-
1 concentrations in patients with TAO only may sug-
gest that soluble ELAM-1 could be a specific marker of
endothelium activation in TAO [2]. Pappa et al. found
that in early untreated active TAO the interstitial and
perimysial connective tissue surrounding the extraocular
muscles fibres and numerous mononuclear cells stained
strongly for ICAM-1. Vascular endothelial cells stained
strongly for VCAM-1 and ICAM-1 [10]. Similar results
have been reported by other authors [11]. In late dise-
ase the same distribution of immunoreactivity for ICAM-
1 and VCAM-1 was observed but with significantly lo-
wer staining. The authors concluded that an increased
expression of adhesion molecules correlated with early
active disease and was reduced in later stages in
a way consistent with the results of our study [10].
Wenisch et al. found that serum levels of sICAM-1
and sVCAM-1 were markedly elevated in patients with
Graves’ diseases before treatment with thiamazole [12].
The serum levels of sELAM-1 and sVCAM-1 decreased
significantly after thiamazole therapy and were within
the normal range after 4 and 8 weeks of therapy respec-
tively. Serum levels of sICAM-1 were elevated even after
8 weeks of therapy. The authors found that serum le-
vels of sVACM-1 and sICAM-1 correlated with the se-
rum concentrations of anti-thyroid-stimulating hormo-
ne (TSH)-receptor antibodies (TSHR-R) and anti-thy-
roid peroxidase antibodies (TPO-Ab), which is consi-
stent with the results of our study. Similar results have
been reported by other authors [13, 14], who found that
serum levels of sICAM-1, sVCAM-1 and sP-selectin were
markedly elevated in patients with Graves’ disease be-
fore treatment with methimazole. After 24 months of
therapy serum concentrations of sVCAM-1 and sP-se-
lectin were normalised, whereas serum levels of sICAM-
1 remained elevated. Serum levels of sICAM-1, sVCAM-
1 and sP-selectin in patients with Graves’ disease corre-
lated with the serum concentrations of triiodothyroni-
ne and thyroxine. Moreover, a positive correlation has
been found between serum levels of TPO-Ab, TG-Ab,
TRAb and sICAM-1 and sVCAM-1 [13]. In a recent stu-
dy, Kulig et al. [15] found that in patients both at an
active stage of the disease and with fibrotic changes in
muscles on MR scans responded well to therapy in pa-
rallel with a significant decrease in levels of sICAM-1
and sVCAM-1. Levels of sVCAM-1 increased slightly
under prednisone treatment despite an improvement
in the clinical picture of TAO and a significant decrease
in sICAM-1 levels and in the number of muscles with
active inflammatory processes on MR scans. It was conc-
luded that serum levels of ICAM-1 seem to be more sen-
sitive as a marker than MR in assessment of the activity
of TAO, but sVCAM-1 does not correspond to the clini-
cal picture of the disease [14]. In contrast to our results,
those of Komorowski et al. [6] indicated that thyroid
function, but not the presence of TAO itself, is probably
responsible for the elevated levels of sICAM and
sVCAM. After methyloprednisolone treatment signifi-
cantly increased levels of sICAM and sVCAM were still
found in hyperthyroid patients compared with the con-
trol group, but normal serum levels of sVCAM before
and after methylprednisolone treatment were found in
euthyroid TAO patients [6].
The reduction of ICAM-1 and/or VCAM-1 in rela-
tion to methylprednisolone treatment has also been re-
ported in other autoimmune and inflammatory disor-
ders [16]. It is suggested that the ICAM-1 and/or VCAM-
1 reduction is due to a peripheral systemic effect on
immune-competent cells, and so the observed reduc-
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tion might also be a non-specific effect of the methyl-
prednisolone treatment. The effect of methylpredniso-
lone on the blood concentration of adhesion molecules
may not be specific for patients with thyroid-associa-
ted orbitopathy.
Conclusion
On the basis of our results we conclude that inflamma-
tion in the orbit and/or in the thyroid gland itself, but
not thyroid function, is probably responsible for the ele-
vated level of the studied adhesion molecules. Evalu-
ation of adhesion molecule concentrations in the blood
of patients with TAO, in association with clinical signs
(CAS) and orbit MR scans, could be one of the parame-
ters for the evaluation of TAO activity and response to
the immunosuppressive treatment, although further
studies are still necessary.
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